Article
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
Leukemia - 1 Apr 2017
Schlenk R F, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau I W, Verbeek W, Heidel F H, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K
Abstract excerpt
Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a phase 2 study of pomalidomide in patients with MPN-associated myelofibrosis and anaemia and/or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.